Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hormone replacement therapy: time to move on?

Dennis A Davey1

  • 1Department of Obstetrics and Gynaecology, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, South Africa 7945. profdad@eject.co.za

The Journal of the British Menopause Society
|June 17, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevention of Alzheimer's disease, cerebrovascular disease and dementia in women: the case for menopause hormone therapy.

Neurodegenerative disease management·2017
Same author

Alzheimer's disease and vascular dementia: one potentially preventable and modifiable disease. Part I: Pathology, diagnosis and screening.

Neurodegenerative disease management·2014
Same author

Alzheimer's disease and vascular dementia: one potentially preventable and modifiable disease? Part II: Management, prevention and future perspective.

Neurodegenerative disease management·2014
Same author

Alzheimer's disease, dementia, mild cognitive impairment and the menopause: a 'window of opportunity'?

Women's health (London, England)·2013
Same author

HRT: some unresolved clinical issues in breast cancer, endometrial cancer and premature ovarian insufficiency.

Women's health (London, England)·2012
Same author

Androgens in women before and after the menopause and post bilateral oophorectomy: clinical effects and indications for testosterone therapy.

Women's health (London, England)·2012

Hormone replacement therapy (HRT) risks and benefits require balanced perspective. Absolute risks, not just relative, are key, especially for younger women, and symptom relief often outweighs rare long-term risks.

Area of Science:

  • Menopause and Hormone Therapy
  • Clinical Risk Assessment
  • Women's Health

Background:

  • Hormone replacement therapy (HRT) decisions require careful risk-benefit analysis.
  • Traditional analyses often focus on relative risks, overlooking absolute and attributable risks.
  • Understanding these risks is crucial for informed patient choices.

Purpose of the Study:

  • To re-evaluate the risks and benefits of hormone replacement therapy (HRT).
  • To emphasize the importance of absolute and attributable risks over relative risks in clinical decision-making.
  • To provide a balanced perspective on HRT for postmenopausal women.

Main Methods:

  • Analysis of clinical trial data, focusing on absolute and attributable risks.
  • Categorization of adverse event frequencies (rare, very rare) based on international recommendations.

Related Experiment Videos

  • Comparison of risks in the Women's Health Initiative (WHI) trial population with typical HRT users.

    • Main Results:

    • Appreciable attributable risks in the WHI trial were mainly observed in women over 70, excluding venous thromboembolism and stroke.
    • The WHI trial population may not represent younger, healthier postmenopausal women commonly prescribed HRT.
    • The benefit of menopausal symptom relief was not fully accounted for in risk-benefit analyses.

    Conclusions:

    • Age is a significant factor in HRT risk assessment, suggesting age-based management guidelines.
    • Many women may have avoided or discontinued HRT due to misunderstood or disproportionately feared risks.
    • Informed decisions about HRT can be made by postmenopausal women and their advisors, considering both risks and benefits.